Standout Papers

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma... 1995 2026 2005 2015 1.5k
  1. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 (1999)
    Michael B. Atkins, Michael T. Lotze et al. Journal of Clinical Oncology
  2. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (1995)
    G. Fyfe, Richard I. Fisher et al. Journal of Clinical Oncology
  3. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  4. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (2012)
    Kim Margolin, Marc S. Ernstoff et al. The Lancet Oncology
  5. Programmed death ligand-1 expression in non-small cell lung cancer (2013)
    Vamsidhar Velcheti, Kurt A. Schalper et al. Laboratory Investigation
  6. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma (2002)
    John Toso, Vee J. Gill et al. Journal of Clinical Oncology
  7. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
    David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology
  8. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  9. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors (2018)
    Angeliki M. Stamatouli, Zoe Quandt et al. Diabetes
  10. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016)
    Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research
  11. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011)
    Jianda Yuan, Matthew Adamow et al. Proceedings of the National Academy of Sciences
  12. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma (2022)
    Alexander X. Lozano, Aadel A. Chaudhuri et al. Nature Medicine

Immediate Impact

12 by Nobel laureates 16 from Science/Nature 171 standout
Sub-graph 1 of 16

Citing Papers

Probiotic-guided CAR-T cells for solid tumor targeting
2023 StandoutScience
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
65 intermediate papers

Works of Mario Sznol being referenced

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
2022 Standout
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
2019 Standout
and 40 more

Author Peers

Author Last Decade Papers Cites
Mario Sznol 13619 7664 5480 266 19.4k
Robert H. Vonderheide 14819 13907 6700 221 24.3k
Patrick Hwu 10549 7628 6521 196 17.0k
Omid Hamid 20826 9634 7834 407 25.6k
Louis M. Weiner 8335 5194 6465 254 16.2k
Sandra Demaria 14383 10343 3523 191 21.1k
Catherine Sautès‐Fridman 14429 15615 8164 300 28.2k
Michele Maio 11151 6794 7186 371 18.0k
David P. Carbone 13377 8966 10758 408 26.4k
Silvia C. Formenti 15199 9581 4992 346 26.4k
Padmanee Sharma 19463 13562 6273 254 27.6k

All Works

Loading papers...

Rankless by CCL
2026